Fournier’s Gangrene under Sodium–Glucose Cotransporter-2 Inhibitors Therapy in Gynecological Patients

Adriana Serrano Olave, Ana Isabel Bueno Moral, Carmen Martínez Bañón, Ernesto González Mesa and Jesús S. Jiménez López
Additional contact information
Adriana Serrano Olave: Obstetrics and Gynecology, Materno-Infantil Hospital Regional Universitario Malaga, Avd Arroyo de los Angeles S/N, 29011 Malaga, Spain
Ana Isabel Bueno Moral: Obstetrics and Gynecology, Materno-Infantil Hospital Regional Universitario Malaga, Avd Arroyo de los Angeles S/N, 29011 Malaga, Spain
Carmen Martínez Bañón: Obstetrics and Gynecology, Materno-Infantil Hospital Regional Universitario Malaga, Avd Arroyo de los Angeles S/N, 29011 Malaga, Spain
Ernesto González Mesa: Obstetrics and Gynecology, Materno-Infantil Hospital Regional Universitario Malaga, Avd Arroyo de los Angeles S/N, 29011 Malaga, Spain
Jesús S. Jiménez López: Obstetrics and Gynecology, Materno-Infantil Hospital Regional Universitario Malaga, Avd Arroyo de los Angeles S/N, 29011 Malaga, Spain

IJERPH, 2022, vol. 19, issue 10, 1-9

Abstract: Fournier’s gangrene (FG) is a serious pathology of the soft tissues and fascia of the perineum and genital region with a high morbidity and mortality rate. In recent years, the SGLT-2 inhibitor oral antidiabetic has been related to this entity. According to the new warnings from the main drug agencies, a compilation of cases has been initiated to establish or deny a possible causal relationship. Most of these cases have been reported in men. However, it is important not to underestimate this entity in the gynecological field, since it is extremely serious and requires intense and rapid aggressive treatment based on surgery and empiric antibiotherapy. Later, some cares are needed to involve surgical reconstruction of the defects introduced by debridement. As a result of the low incidence of FG, clinical trials’ data may be insufficient to robustly assess this issue because of the limited numbers of participants. Real-world evidence may help to clarify the association between SGLT2i and FG. The aim of this review is to describe and compare the reported cases of GF in diabetic women who received SGLT2 inhibitors as antiglycemic agents.

Keywords: gangrene; SGLT-2 inhibitor; diabetes; genital lump; gas; emphysema; surgery (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/10/6261/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/10/6261/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:10:p:6261-:d:820661

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().